Trial ID or NCT#

NCT02303431

Status

RECRUITING

Purpose

This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug (pharmacokinetics) and what the drug does to the body (pharmacodynamics), and to compare if these effects are similar to those observed in adults.

Official Title

A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients

Eligibility Criteria

Ages Eligible for Study: Younger than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Michael Jeng
Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital

Contact us to find out if this trial is right for you.

CONTACT

Jeff Vasallo
(513) 579-9911